CL2015001936A1 - Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif). - Google Patents

Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).

Info

Publication number
CL2015001936A1
CL2015001936A1 CL2015001936A CL2015001936A CL2015001936A1 CL 2015001936 A1 CL2015001936 A1 CL 2015001936A1 CL 2015001936 A CL2015001936 A CL 2015001936A CL 2015001936 A CL2015001936 A CL 2015001936A CL 2015001936 A1 CL2015001936 A1 CL 2015001936A1
Authority
CL
Chile
Prior art keywords
hif
hypoxia
prepare
serves
composition
Prior art date
Application number
CL2015001936A
Other languages
English (en)
Inventor
David A Ross
Ralph Christian Crumrine
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of CL2015001936A1 publication Critical patent/CL2015001936A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CL2015001936A 2014-07-11 2015-07-08 Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif). CL2015001936A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462023446P 2014-07-11 2014-07-11

Publications (1)

Publication Number Publication Date
CL2015001936A1 true CL2015001936A1 (es) 2015-12-28

Family

ID=53385523

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001936A CL2015001936A1 (es) 2014-07-11 2015-07-08 Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).

Country Status (25)

Country Link
US (2) US9687530B2 (es)
EP (3) EP2977056B1 (es)
JP (1) JP6517100B2 (es)
KR (3) KR102219557B1 (es)
CN (1) CN105288598A (es)
AR (1) AR101133A1 (es)
AU (3) AU2015203264B2 (es)
BR (1) BR102015015916A2 (es)
CA (3) CA3191469A1 (es)
CL (1) CL2015001936A1 (es)
ES (2) ES2693602T3 (es)
HK (1) HK1220895A1 (es)
HU (1) HUE053104T2 (es)
IL (1) IL239655B (es)
MX (1) MX359029B (es)
MY (1) MY184341A (es)
NZ (2) NZ709399A (es)
PL (2) PL3300742T3 (es)
PT (2) PT3300742T (es)
RU (1) RU2686308C2 (es)
SG (2) SG10201505207RA (es)
TR (1) TR201815058T4 (es)
TW (1) TWI704926B (es)
UY (1) UY36173A (es)
ZA (2) ZA201504705B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107831315B (zh) * 2017-10-31 2019-11-05 中国科学院昆明动物研究所 转铁蛋白标志物及其应用
MX2022016227A (es) * 2020-07-08 2023-02-01 Grifols Worldwide Operations Ltd Composiciones que tienen aplicaciones neuroregenerativas.
AR122901A1 (es) * 2020-07-08 2022-10-12 Grifols Worldwide Operations Ltd Composiciones que tienen aplicaciones neuroregenerativas
RU2747653C1 (ru) * 2021-01-11 2021-05-11 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ диагностики нарушения обмена железа при тяжелых формах covid-19
EP4052723A1 (en) 2021-03-02 2022-09-07 Grifols Worldwide Operations Limited Alpha-1 antitrypsin dosing regimen
EP4311556A1 (en) 2022-07-28 2024-01-31 Grifols Worldwide Operations Limited Antithrombin in stroke

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5986067A (en) * 1991-02-08 1999-11-16 The University Of Vermont And State Agricultural College Recombinant transferrins, transferrin half-molecules and mutants thereof
AU4553793A (en) * 1992-07-10 1994-01-31 University Of British Columbia, The Use of p97 and iron binding proteins as diagnostic and therapeutic agents
IT1278136B1 (it) * 1995-07-12 1997-11-17 Piera Valenti Associazione costituita dsa lattoferrina (o suoi analoghi) e deferossamina metalsulfonato (o altri chelanti ioni metallici) per
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6004986A (en) * 1997-05-08 1999-12-21 The University Of Virginia Patent Foundation Method for treating cerebral vasospasm and cerebral ischemia using iron chelators and pharmaceutical compositions therefor
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US20020164571A1 (en) 2001-03-02 2002-11-07 Hammerman Marc R. Method of preserving metanephroi in vitro prior to transplantation
US20030153503A1 (en) 2001-12-06 2003-08-14 Klaus Stephen J. Methods of increasing endogenous erythropoietin (EPO)
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
WO2007048004A2 (en) * 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
US20070149440A1 (en) * 2005-12-28 2007-06-28 Essential Skincare, Llc Transferrin and transferrin-based compositions for diabetes treatment
EP1988917A4 (en) * 2005-12-28 2009-08-19 Zoltan Lab Llc COMPOSITIONS AND METHODS FOR INCREASING THE VITABILITY AND FUNCTION OF ISLAND CELLS
EP4095127A1 (en) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
WO2008113134A1 (en) * 2007-03-20 2008-09-25 Garvan Institute Of Medical Research Method of transplantation of a kidney
ITLU20070009A1 (it) * 2007-05-21 2008-11-22 Kedrion Spa Uso di transferrina per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni batteriche come coadiuvanti nella terapia antibiotica.
US8309583B2 (en) * 2007-11-01 2012-11-13 Rachel Codd Desferrioxamine conjugates, derivatives and analogues
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
WO2013054470A1 (ja) 2011-10-12 2013-04-18 Ｓｂｉファーマ株式会社 移植臓器生着促進剤
EP2776058B2 (en) * 2011-11-11 2019-03-20 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Apotransferrin for the treatment of brain stroke
US9763899B2 (en) * 2012-08-30 2017-09-19 The Board Of Trustees Of The Leland Stanford Junior University Iron chelators and use thereof for reducing transplant failure during rejection episodes

Also Published As

Publication number Publication date
AU2021201445B2 (en) 2024-02-29
CA3191469A1 (en) 2016-01-11
PL3300742T3 (pl) 2021-05-04
EP2977056A2 (en) 2016-01-27
EP3795171B1 (en) 2024-04-10
ES2693602T3 (es) 2018-12-12
MX2015008310A (es) 2016-01-11
KR102310000B1 (ko) 2021-10-07
CA3191475A1 (en) 2016-01-11
EP2977056B1 (en) 2018-09-12
BR102015015916A2 (pt) 2016-01-12
EP2977056A3 (en) 2016-04-27
CA2894239C (en) 2023-05-09
TR201815058T4 (tr) 2018-11-21
JP6517100B2 (ja) 2019-05-22
SG10201811078XA (en) 2019-01-30
EP3300742A1 (en) 2018-04-04
EP3795171A1 (en) 2021-03-24
AU2015203264A1 (en) 2016-01-28
HK1220895A1 (zh) 2017-05-19
AR101133A1 (es) 2016-11-23
RU2015126920A (ru) 2017-01-10
PT2977056T (pt) 2018-11-07
NZ709399A (en) 2019-10-25
AU2021201445A1 (en) 2021-03-25
UY36173A (es) 2016-02-29
AU2019264588A1 (en) 2019-12-05
MY184341A (en) 2021-04-01
RU2686308C2 (ru) 2019-04-25
EP3300742B1 (en) 2020-11-04
NZ757595A (en) 2024-01-26
USRE49129E1 (en) 2022-07-12
SG10201505207RA (en) 2016-02-26
US20160008437A1 (en) 2016-01-14
ZA202203445B (en) 2022-09-28
ES2843783T3 (es) 2021-07-20
MX359029B (es) 2018-09-12
JP2016020342A (ja) 2016-02-04
US9687530B2 (en) 2017-06-27
HUE053104T2 (hu) 2021-06-28
TW201622742A (zh) 2016-07-01
TWI704926B (zh) 2020-09-21
PT3300742T (pt) 2021-01-25
AU2015203264B2 (en) 2019-08-22
KR20160007367A (ko) 2016-01-20
KR20190132966A (ko) 2019-11-29
KR102219557B1 (ko) 2021-02-24
CA2894239A1 (en) 2016-01-11
CN105288598A (zh) 2016-02-03
KR20210021339A (ko) 2021-02-25
IL239655B (en) 2019-07-31
RU2015126920A3 (es) 2019-01-15
PL2977056T3 (pl) 2019-03-29
AU2019264588B2 (en) 2021-03-25
ZA201504705B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
DK3242887T3 (da) GIP- og GLP-1-co-agonist-forbindelser
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
EA201691582A1 (ru) Новые фармацевтические препараты
DK3199546T3 (da) Oxyntomodulin-analog
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2015001936A1 (es) Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
BR112016026879A2 (pt) Composição farmacêutica líquida
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
FR3030155B1 (fr) Multiplexeur analogique
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
BR112016026143A2 (pt) os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.
BR112016026470A2 (pt) Composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
BR112016030507A2 (pt) Compostos relacionados à vitamina d, composição farmacêutica, e kit
BR112016021875A2 (pt) composição tópica
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
ITUB20156000A1 (it) Composizione nematocida e suo utilizzo
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma